Now in its tenth year of operation, PBL's TEC Scheme continues to be an extremely successful route for promoting new plant bioscience innovations to industry. In the past three years alone, PBL has offered through the scheme 25 new innovations from 17 different public research institutions in 8 different countries around the world. These include innovations offered by PBL on behalf of INRA Transfert, the technology transfer organisation of the French national agricultural research organisation, INRA. Since January 2010, 37 evaluation licences have been taken by the industry members of the TEC Scheme. Nine of these evaluation agreements also included options to obtain a commercial licence at a later date. Also over the same period, 15 commercial licences have been signed by PBL for technologies promoted through the TEC Scheme, which remains extremely popular with the plant technology industry.
PBL has recently achieved the grant of various patents from its biocontrol technologies portfolio. While the first patent for the cis-jasmone technology from Rothamsted Research was granted in 2005 (together with grants in Europe and Canada in the same year), the newly granted US Patent No. 8,221,736 extends the scope of the patent cover. In addition the synergist technology (also from RRes) that supports the cis-jasmone technology will grant in the US in the next few months.
Plant Bioscience Limited (PBL) is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 8,299,235 with fundamental claims directed to compositions to effect gene silencing.
In October 2012, PBL and OBP (Onderstepoort Biological Products SOC Limited) signed a research and development licence for OBP to use the HT-CPMV system developed by George Lomonossoff and Frank Sainsbury at the John Innes Centre to develop vaccines for use in important animal health applications. Previous tests have already shown the successful vaccination of sheep with a blue tongue virus vaccine. The agreement includes the option to obtain a commercial licence, if the development phase is successful.
In 2010 we announced our technology development partnerships with the Jilin Academy of Agricultural Sciences (JAAS) and the Institute of Botany, Chinese Academy of Sciences (IB-CAS), under which these partners will make and test transgenic crop plants containing technologies from PBL's portfolio. In a further new direction, PBL is delighted to announce taking on our first new technology invented in a Chinese research institution. In October, PBL started marketing a new plant biotechnology innovation from one of the leading Chinese Academy of Sciences institutes, the Institute of Genetics and Developmental Biology (IGDB). The new technology has already been well received by the international agricultural biotechnology industry.
Plant Bioscience Limited (PBL) is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued out US Patent No. 8,258,285 with fundamental claims directed to compositions to effect gene silencing and US Patent No. 8,263,569 with fundamental claims directed to methods of inducing gene silencing using short RNA molecules, or DNA constructs encoding short RNA molecules, in a wide range of organisms, including in plants and humans.
The world’s largest prostate cancer charity is to fund a UK study of the protective effects of broccoli consumption.
Alnylam Pharmaceuticals, Inc (Nasdaq: ALNY), a leading RNAi therapeutics company. PBL has granted Alnylam a world-wide, non-exclusive license to the Baulcombe patent (US Patent No. 8,097,710) for use in the field of human therapeutics.
Please click here to read article in full, and here for a link to the Short RNA section on our website.
For more information, please contact Dr Lars von Borcke.
The system (CPMV and CPMV-HT Protein Expression) is faster than current methods and so it offers an extremely effective way of making proteins such as vaccines rapidly, as needs arise. His work is already being used by Medicago, a Canadian biotechnology company, to develop a vaccine for the H5N1 avian influenza virus under licence from PBL.
Please click here to read article in full.
Other technologies developed by George Lomonossoff are also available from PBL:
04.355 - CPMV RNA Mimics
09.474 - Empty VLP Nanoshells
For more information on these technologies, please contact Dr Lars von Borcke.
8,097,710 with fundamental claims directed to methods of inducing gene silencing using short RNA molecules, or DNA constructs encoding short RNA molecules, in a wide range of organisms, including in plants and humans.
To see the full press release, please click here.
For licensing enquiries, please contact Dr Lars von Borcke. All other enquiries to firstname.lastname@example.org.
4 January 2012: Today, the Biotechnology and Biological Sciences Research Council (BBSRC) publishes its Impact Report 2011. The report details BBSRC's on-going efforts to ensure that BBSRC-funded research in basic biology can be fully exploited to deliver economic and social benefits for the UK.
|©2006 PBL Technology|